NN-6434 is under clinical development by Novo Nordisk and currently in Phase II for Atherosclerosis. According to GlobalData, Phase II drugs for Atherosclerosis have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NN-6434’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NNC-03850434 (NN-6434) is under development for the treatment of familial hypercholesterolaemia, hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD). It is administered via subcutaneous and oral route. The drug candidate acts by targeting Proprotein Convertase Subtilisin/Kexin Type 9. The drug candidate is a peptide.
Novo Nordisk overview
Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
For a complete picture of NN-6434’s drug-specific PTSR and LoA scores, buy the report here.